ABSTRACT
There is growing evidence that obesity, and particularly
central obesity, has an important impact on predisposing
risk factors for coronary heart disease, including dysli-
pidemia, glucose intolerance, insulin resistance, and
elevated blood pressure (1,2). Reversal of these meta-
bolic abnormalities associated with obesity is one of the
most important targets in the clinical management of
obesity.
